Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Antoniucci, David (7005655782)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: The MASTER study
    (2019)
    Valdes-Chavarri, Mariano (57216641409)
    ;
    Kedev, Sasko (23970691700)
    ;
    Neskovic, Aleksandar N. (35597744900)
    ;
    de la Tassa, Cesar Morís (57222430348)
    ;
    Zivkovic, Milan (57535325700)
    ;
    Nouche, Ramiro Trillo (6506199560)
    ;
    González, Nicolas Vázquez (56152454100)
    ;
    Bartorelli, Antonio L. (7005844246)
    ;
    Antoniucci, David (7005655782)
    ;
    Tamburino, Corrado (57212260375)
    ;
    Colombo, Antonio (35354455800)
    ;
    Abizaid, Alexandre (36122299200)
    ;
    McFadden, Eugene (55510816600)
    ;
    García-García, Hector M. (9633803100)
    ;
    Milasinovic, Dejan (24823024500)
    ;
    Stankovic, Goran (59150945500)
    Aims: The MASTER study was designed to compare the performance of a new biodegradable polymer sirolimus-eluting stent (BP-SES) with a bare metal stent (BMS) in patients with ST-segment elevation myocardial infarction (STEMI). Methods and results: The study was a prospective, randomised (3:1), controlled, single-blind multicentre trial that enrolled 500 STEMI patients within 24 hours of symptom onset during 2013-2015. Three hundred and seventy-five patients were treated with BP-SES and 125 with BMS. One hundred and four (104) randomised patients underwent angiographic follow-up at six months. The primary clinical endpoint was target vessel failure (TVF), defined as cardiac death, MI not clearly attributable to a non-target vessel, or clinically driven target vessel revascularisation (TVR) at 12 months. The primary angiographic endpoint was in-stent late lumen loss (LLL) at six months in the angiographic cohort. The major secondary endpoint for safety was a composite of all-cause death, recurrent MI, unplanned infarct-related artery revascularisation, stroke, definite stent thrombosis (ST) or major bleeding at one month. At 12 months, TVF had occurred in 6.1% of BP-SES and 14.4% of BMS patients (pnon-inferiority=0.0004), mainly driven by a higher rate of repeat revascularisation in BMS patients. The safety endpoint occurred in 3.5% of BP-SES and 7.2% of BMS patients (p=0.127). In-stent LLL demonstrated the superiority (p=0.0125) of BP-SES (0.09±0.43 mm) over BMS (0.79±0.67 mm). Conclusions: The study showed clinical non-inferiority and angiographic superiority of BP-SES versus a comparator BMS, suggesting that this novel DES may be a potential treatment option in STEMI. © Europa Digital & Publishing 2019. All rights reserved.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback